University of Utah's Huntsman Cancer Institute selects Mevion's compact single-chamber system for Utah's first proton therapy center
Wednesday, October 10, 2018
Mevion Medical System announced that the University of Utah (U of U) Huntsman Cancer Institute (HCI) has signed a contract to purchase a HYPERSCAN Pencil MEVION S250i Proton Therapy SystemTM with Beam Scanning TM (PBS) technology .
Dennis Shrieve, MD, PhD , HCI Tumor Radiologist, Professor and Director of Tumor Radiotherapy at the University of Utah , said: "The HCI Proton Therapy Center will provide another unique and technologically advanced for the Western Mountain Patients in the United States, which HCI and our cancer experts will receive. Tumor radiotherapy solutions."
Proton therapy is a precise radiotherapy that reduces unwanted radiation exposure in healthy tissues. This advantage is expected to reduce side effects, increase doses, and reduce the risk of secondary malignancies, which are especially important in pediatric cases.
However, the land occupation and cost of old proton technology has become a major obstacle to the promotion of proton therapy. Mevion has adopted a different approach to designing proton therapy systems, which overcomes the practical challenges of earlier technologies, with the result that solutions for both land and price are significantly reduced.
At HCI, the proton center is built on a small piece of available space adjacent to the existing radiotherapy unit, which greatly increases efficiency and economy. HCI's planning includes the option to build a second site in the future, which is only possible through the compact nature of the Mevion solution.
Bill Salter, PhD , director of HCI Tumor Radiotherapy, and director of the Department of Medical Physics at the University of Utah , said: "At HCI, we have been closely tracking the evolution of proton technology for ten years. Proton therapy benefits from the latest major technological advances, adding it to our The lineup of radiotherapy technology and the expertise of our cancer center is an exciting time."
HCI's system will be equipped with Mevion's HYPERSCAN Pencil Beam Scanning delivery system. This technology has improved the old scanning technology, especially thanks to Mevion's Adaptive ApertureTM, a new proton multi-leaf collimator (pMLC) that provides clinicians with the most compliant treatment.
Mevion Medical Systems CEO Tina Yu, Ph.D. said: "Mevion is proud to partner with the prestigious Huntsman Cancer Institute to open Utah's first proton therapy center. Our mission is to make protons accessible to all cancer patients. Treatment, we are heartened by the fact that patients and their families in western Utah and the surrounding mountains can take this advanced treatment without having to travel long distances."
The HCI Proton Therapy Center is scheduled to be open to patients in the second half of 2020.
Accelerate global promotion
In addition to the Huntsman Cancer Center, the MEVION S250iTM system continues to be the preferred system for leading cancer centers. There are also two HYPERSCAN centers that are in the final stages of installation and will treat patients by the end of 2018. Two other centers are in the planning stage, both of which are examples of the addition of a second Mevion system to the existing site after the first system is installed.
About Mevion Medical Systems®
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for radiation therapy for cancer patients. Headquartered in Littleton, Massachusetts, Mevion has offices in Europe and China. For further information, please visit www.mevion.com .
Follow Mevion on Twitter: https://twitter.com/mevionmedical
Follow Mevion on LinkedIn: https://www.linkedin.com/company/mevion-medical-systems
Disclaimer: The original version of this announcement is an officially licensed version. The translation is for your convenience only. Please refer to the original text. The original version is the only legally valid version.
Contacts
Mevion Medical Systems, Inc.
Melanie Benton, 978-540-1551
mbenton@mevion.com